{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(1)"],"submitter":["Carey LA"],"funding":["Gilead Sciences, Inc."],"pubmed_abstract":["Patients with triple-negative breast cancer (TNBC) who relapse early after (neo)adjuvant chemotherapy have more aggressive disease. In the ASCENT trial, sacituzumab govitecan (SG), an antibody-drug conjugate composed of an anti-Trop-2 antibody coupled to SN-38 via a hydrolyzable linker, improved outcomes over single-agent chemotherapy of physician's choice (TPC) in metastatic TNBC (mTNBC). Of 468 patients without known baseline brain metastases, 33/235 vs 32/233 patients (both 14%) in the SG vs TPC arms, respectively, received one line of therapy in the metastatic setting and experienced disease recurrence ≤12 months after (neo)adjuvant chemotherapy. SG prolonged progression-free survival (median 5.7 vs 1.5 months [HR, 0.41; 95% CI, 0.22-0.76]) and overall survival (median 10.9 vs 4.9 mont"],"journal":["NPJ breast cancer"],"pagination":["72"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9184615"],"repository":["biostudies-literature"],"pubmed_title":["Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis."],"pmcid":["PMC9184615"],"pubmed_authors":["Rugo HS","Zhu Y","Diamond JR","Fontaine C","Punie K","Wang G","Kalinsky K","Dalenc F","Hurvitz SA","Loirat D","Bardia A","Dieras V","Phan S","Piccart M","Carey LA","Delaney R","O'Shaughnessy J","Loibl S","Cortes J","Gianni L"],"additional_accession":[]},"is_claimable":false,"name":"Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis.","description":"Patients with triple-negative breast cancer (TNBC) who relapse early after (neo)adjuvant chemotherapy have more aggressive disease. In the ASCENT trial, sacituzumab govitecan (SG), an antibody-drug conjugate composed of an anti-Trop-2 antibody coupled to SN-38 via a hydrolyzable linker, improved outcomes over single-agent chemotherapy of physician's choice (TPC) in metastatic TNBC (mTNBC). Of 468 patients without known baseline brain metastases, 33/235 vs 32/233 patients (both 14%) in the SG vs TPC arms, respectively, received one line of therapy in the metastatic setting and experienced disease recurrence ≤12 months after (neo)adjuvant chemotherapy. SG prolonged progression-free survival (median 5.7 vs 1.5 months [HR, 0.41; 95% CI, 0.22-0.76]) and overall survival (median 10.9 vs 4.9 mont","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2025-04-04T13:17:13.658Z","creation":"2025-02-19T04:56:36.726Z"},"accession":"S-EPMC9184615","cross_references":{"pubmed":["35680967"],"doi":["10.1038/s41523-022-00439-5"]}}